Real world extension study in patients with atopic dermatitis who participated in previous tralokinumab trials
- Conditions
- L20.9Atopic dermatitis, unspecified
- Registration Number
- DRKS00026128
- Lead Sponsor
- EO Pharma A/S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 63
Inclusion Criteria
Adult patients eligible for treatment with tralokinumab according to the national, approved label where the decision to prescribe tralokinumab has been made prior to and independently of enrolment in the study.
-Signed and dated informed consent.
-Participated in the ECZTEND clinical trial and decision to continue tralokinumab treatment with commercially available drug.
Exclusion Criteria
-Participation in the active treatment phase of a clinical trial.
-Previous enrolment in the study.
-Contraindications according to the label.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective is to evaluate the long-term effect of tralokinumab.
- Secondary Outcome Measures
Name Time Method The secondary objectives are to explore treatment patterns and reasons for treatment changes; to characterize long-term responders; and to evaluate the long-term safety of tralokinumab.